Caplin Point Laboratories
CAPLIPOINT · Pharma > Pharmaceuticals & Drugs · Chairman: C C Paarthipan · MD: Sridhar Ganesan · Listing date: June 23, 2014 · Employees: 1675 · Chennai · http://www.caplinpoint.net

Stock Price vs Company Growth
1d
2.2%
1w
1.1%
1m
3.3%
3m
9.4%
6m
7.5%
1y
18.3%
5y
32.0%
10y
21.8%
all
42.3%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 1,933 2.2%
1,873
2,397
Company Overview

Sales
2,040 Cr
Growth: 12.0%
Profit after Tax
589 Cr
Growth: 4.2%
Mid Cap
14,693 Cr
P/E: 25.1x
Industry P/E: 33.3x
Fundamentals

Sales (Cr) ₹ 2,040
Growth 12.0%
EBITDA 34.2%
P/S 7.2x
Dividend 0.3%
P/E 25.1x
Book Value ₹ 415
PEG Ratio 2.1x
ROE 20.1%
P/B 4.7x
Shareholding Pattern

Institutions
Promoters
P Vijayalakhsmi
23.64 %
Paarthipan C C
18.73 %
Ashok Gorkey Partheeban
11.96 %
Partheeban Vivek Siddarth
11.9 %
May India Property Private Limited
2.8 %
Others
Iepf
2.46 %
Visalatchi
2.22 %
Suresh Kumar Agarwal
1.32 %
Ashish Kacholia
1.16 %
Llp
0.7 %
Increase    Decrease    No change
Company Profile Detailed

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.
Investors (50)
Followers (28)